Showing results (191-200 of 517) with videos related to

Sort By:
Pageof 52
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 20, 2010
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TransplantationSteven Z Pavletic, Shaji Kumar, Mohamad Mohty, et al.
European Journal of Haematology|May 8, 2013
Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myelomaAlexandra J Greenberg, Margot Cousin, Shaji Kumar, et al.
Leukemia & Lymphoma|November 12, 2013
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesTariq I Mughal, Saulius Girnius, Steven T Rosen, et al.
Blood|January 24, 2009
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibitionGiada Bianchi, Laura Oliva, Paolo Cascio, et al.
Expert Opinion on Emerging Drugs|October 30, 2025
Mezigdomide for multiple myeloma: a focus on phase 2 trial dataClifton C Mo, Yuxin Liu, Omar Nadeem, et al.
Expert Review of Hematology|July 26, 2024
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomideYuxin Liu, Clifton C Mo, Monique A Hartley-Brown, et al.
Leukemia Research|August 2, 2006
Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progressionMichael Kline, Kathleen Donovan, Linda Wellik, et al.
Blood|June 26, 2004
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosisSteven Le Gouill, Klaus Podar, Martine Amiot, et al.
American Journal of Hematology|December 23, 2011
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycinVijay Ramakrishnan, Michael Timm, Jessica L Haug, et al.
British Journal of Haematology|December 5, 2009
Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myelomaShirshendu Sinha, S Vincent Rajkumar, Martha Q Lacy, et al.
Pageof 52